The CRADA will allow the WRAIR to conduct preclinical testing on a novel compound derived from Concert’s DCE Platform (deuterated chemical entity platform) for seizure protection associated with traumatic brain injury (TBI).
Concert and WRAIR will share costs on the preclinical efficacy evaluation of the compound.
WRAIR Center of Excellence for Military Psychiatry and Neuroscience’s Brain Trauma Neuroprotection and Neuroplasticity Branch chief Frank Tortella said his laboratory conducts basic and applied research on mechanisms and pathophysiology of brain injury, with a specific focus on developing improved diagnostics and novel neuroprotective therapeutics.
Concert president and CEO Roger Tung said that the partners will further evaluate this novel compound, identify and treat important unmet medical needs such as TBI.